Fairvalue-Calculator Fairvalue-Calculator
EN DE

Biodesix, Inc (BDSX) Fair Value & Analysis

Healthcare · US · Market cap $158M

Price$17.35
Fair Value$29.91
Upside+72.4%
Quality95/100
Evidence: Low Range $22.43 – $37.39

Fair value as of: Jun 23, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Biodesix, Inc (BDSX) currently trades at $17.35, while our model-based Fair Value estimate is $29.91 — implying the stock looks roughly 72.4% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnost…

Open the full interactive analysis →

Similar stocks

Thermo Fisher Scientific Inc (TMO) -56% Danaher Corporation (DHR) -37% WuXi AppTec Co (WUXAY) +35% IDEXX Laboratories, Inc (IDXX) -53% Lonza Group (LZAGY) -74% Agilent Technologies, Inc (A) -50%

Frequently asked questions

Is Biodesix, Inc (BDSX) undervalued?
As of Jun 23, 2026, our model estimates a fair value of $29.91 versus a price of $17.35 — about +72% (undervalued). Model-based estimate, not financial advice.
What is the fair value of BDSX?
Our 21-model fair value for Biodesix, Inc is $29.91 (as of Jun 23, 2026), built from audited fundamentals. The current price is $17.35.
What is the quality score of BDSX?
Biodesix, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.